Literature DB >> 11173616

Prostate Cancer Old Problems and New Approaches. Part III. Prevention and Treatment.

Kenneth V Honn1, Amer Aref, Yong Q Chen, Michael L Cher, John D Crissman, Jeffrey D Forman, Xiang Gao, David Grignon, Maha Hussain, Arthur T Porter, J.Edson Pontes, Bruce Redman, Wael Sakr, Richard Severson, Dean G Tang, David P Wood.   

Abstract

In Part Three of this review, we begin with an analysis of prevention strategies for prostate cancer followed by a discussion of the clinical use of molecular techniques for the evaluation and treatment of patients with clinically localized prostate cancer. New developments in neutron and photon therapy of prostate cancer are addressed as well as the use of systemic radiotherapy for the treatment of bone metastases. Finally, we conclude with the role of hormonal therapy in the treatment of prostate cancer and the current status of development of chemo therapeutic regimens for the treatment of prostate cancer.

Entities:  

Year:  1996        PMID： 11173616     DOI： 10.1007/bf02904824

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


  84 in total

1.  Low dose single fraction radiotherapy in the treatment of metastatic bone pain: a pilot study.

Authors:  P Price; P J Hoskin; D Easton; D Austin; S Palmer; J R Yarnold
Journal:  Radiother Oncol       Date:  1988-08       Impact factor: 6.280

Review 2.  Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review.

Authors:  C W Boone; G J Kelloff; W E Malone
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

Review 3.  Complete androgen blockade for the treatment of prostate cancer.

Authors:  F Labrie; A Dupont; A Belanger
Journal:  Important Adv Oncol       Date:  1985

4.  Reduction of spinal metastases after preemptive irradiation in prostatic cancer.

Authors:  I D Kaplan; R Valdagni; R S Cox; M A Bagshaw
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-05       Impact factor: 7.038

5.  Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.

Authors:  O Sartor; M Cooper; M Weinberger; D Headlee; A Thibault; A Tompkins; S Steinberg; W D Figg; W M Linehan; C E Myers
Journal:  J Natl Cancer Inst       Date:  1994-02-02       Impact factor: 13.506

6.  Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.

Authors:  G R Hudes; R Greenberg; R L Krigel; S Fox; R Scher; S Litwin; P Watts; L Speicher; K Tew; R Comis
Journal:  J Clin Oncol       Date:  1992-11       Impact factor: 44.544

7.  Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.

Authors:  M L Cher; K Chew; W Rosenau; P R Carroll
Journal:  Prostate       Date:  1995-02       Impact factor: 4.104

8.  Treatment of pathological fractures of the hip by endoprosthetic replacement.

Authors:  J M Lane; T P Sculco; S Zolan
Journal:  J Bone Joint Surg Am       Date:  1980-09       Impact factor: 5.284

9.  Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

Authors:  M J Moore; D Osoba; K Murphy; I F Tannock; A Armitage; B Findlay; C Coppin; A Neville; P Venner; J Wilson
Journal:  J Clin Oncol       Date:  1994-04       Impact factor: 44.544

10.  Inhibition of prostate cancer growth by estramustine and colchicine.

Authors:  M Fakih; A Yagoda; T Replogle; J E Lehr; K J Pienta
Journal:  Prostate       Date:  1995-06       Impact factor: 4.104
View more
  1 in total

Review 1.  Molecular pathology of tumor metastasis. I. Predictive pathology.

Authors:  J Tímár; O Csuka; Z Orosz; A Jeney; L Kopper
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.